Background: Theory of Mind (ToM) is the ability to attribute independent mental states to self and others, such as beliefs, desires, emotions and intentions, in order to explain and predict behavior. Previous brain imaging studies of ToM in adults have implicated a widely distributed brain structure including frontal lobes, superior temporal gyri, amygdala and the right tempo-parietal cortex. Initial research in ToM has been focused on autistic children. Investigation of ToM in other neurological and psychiatric populations is more recent and still quite sparse. MS is a chronic demyelinating disease of the CNS. Beside neurological signs, MS may comport disorders of cognition and behavior, which could also reflect the direct consequences of damage to brain structures. Objective: The aim of this study was to assess ToM and recognition of emotions in adults with MS. Methods: A total of 70 patients with MS were compared with 30 matched healthy controls. Subjects were explored with six tests of ToM (two first-order false belief tasks, two second-order false belief and two social 'faux-pas' tasks) and a facial emotion recognition task. We also examined the relationship of ToM performances with executive functioning tasks. Results: Results showed that MS patients performed significantly worse than controls in recognition of facial expressions of anger and fear. They scored also significantly lower on all tests of ToM. MS patients performed well on control questions designed to assess general comprehension and memory. Moreover, none of the executive functions measures was correlated with the ToM abilities, suggesting a relative independence between these two processes. Conclusions: To our knowledge, this is the first study suggesting that impairment of social behavior in MS patients could be, at least partly, linked to ToM impairments and to disturbances in decoding facial emotional expressions.
Background: Multiple sclerosis (MS) patients experience a wide spectrum of cognitive deficits, and verbal memory deficits are common. Verbal encoding is dependent on the medial temporal lobe (MTL) and the hippocampus. Previous functional magnetic resonance imaging (fMRI) studies show that in normal learning, encoding activates the anterior CA1-3 and dentate gyrus (antCADG) regions of the hippocampus. We recently demonstrated reductions in hippocampal gray matter volume localized to the CA1 subregion in early MS patients and significant loss in all hippocampal regions in secondary progressive patients. Objective: To assess whether alterations in hippocampal functional activity are present in MS, and if they contribute to verbal memory deficits, fMRI and a novel cortical unfolding technique were used to investigate BOLD signal differences in specific subregions of the hippocampus and MTL during a verbal memory task. Methods: High-resolution structural and functional MRIs were acquired for each subject at 3.0T. An unrelated word-pairs test was used to determine verbal memory performance. Cortical unfolding of the hippocampus and nearby MTL was performed using a previously described technique. After interpolation, flattened templates had an isotropic resolution of 0.4 mm and demarcated 10 specific subregions. Significant group activations, corrected for multiple comparisons, were then overlaid on combined group templates to show subregion-specific activity during encoding and recall. Results: During the task, patients required more trials than controls to learn all word pairs. Controls showed activations specific to the antCADG during encoding, consistent with previous literature. Patients did not show this same pattern, but instead showed extra-hippocampal activity localized to the perirhinal cortex. Conclusions: While MS affects hippocampal volume, it is unknown how these structural changes contribute to verbal memory deficits. Using fMRI, we find that MS patients deviate from normal activation patterns in the antCADG region during encoding. Patients instead demonstrate greater activity in the perirhinal cortex, a region that inputs into the hippocampus via the entorhinal cortex. These differences may account for verbal memory deficits. Supported by: Claire and William Vaughn, National Multiple Sclerosis Society RG3914, Skirball Foundation. 
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Specific CNS recruitment and suppressive function of HLA-G expressing regulatory T cells in the target organ of patients with multiple sclerosis
University of Heidelberg, Heidelberg, Germany
Background: Neurodegeneration is an important feature of multiple sclerosis (MS) while the underlying mechanisms of axonal loss are poorly understood. For a number of reasons it is reasonable to assume that tandem pore domain potassium channels (K 2 P) most likely play a major role within this context. Objective: Here, we investigated whether K 2 P channel TASK1 contributes to neurodegeneration in experimental autoimmune encephalomyelitis (EAE). Methods: We used enzyme-linked immunoabsorbent assay (ELISA), proliferation assays, FACS analysis and electrophysiological measurements to characterize T lymphocytes of TASK1 knockout mice. EAE was induced with MOG peptide in wildtype mice and knockout mice. Neurodegeneration was measured by immunohistochemical staining of spinal cord sections and by magnetic resonance imaging (MRI) of mouse brain. Results: TASK1 is expressed on T cells and neurons. After induction of EAE(MOG35-55), TASK1
-/-mice showed a significantly reduced clinical severity and markedly reduced axonal degeneration compared with wild type controls. T cells from TASK1 -/-mice displayed impaired T cell proliferation and cytokine production, while TASK1 -/-mice have a normal immune repertoire. Anandamide, an inhibitor of TASK channels, reduced T cell outward currents and inhibited T-cell effector functions, an effect completely abrogated in TASK1 -/-mice. Accordingly, preventive blockade of TASK1 significantly ameliorated EAE after immunization. Therapeutic application of anandamide was curative and capable of stopping progressive loss of brain volume as assessed by MRI. TASK1 expression in human MS lesions supports the identification of TASK1 as molecular target for the therapy of inflammatory and degenerative CNS disorders. Conclusions: Besides this direct impact on CNS neurons and axons, TASK1 channels critically influence T cell effector function, thereby providing a dual mechanism of action contributing to T-cell mediated inflammation and neuronal degeneration. Background: Although the presence of leukocytes within MS lesions is indisputable, the route and adhesion molecules by which these cells access the brain are still not fully understood. Objective: Using a lipid raft-based proteomic approach we identified MCAM/CD146 as an immunoglobulin superfamily member potentially involved in leukocyte migration across the blood-brain barrier (BBB). Methods: Using an in vitro model of the human BBB and the animal model of MS, experimental autoimmune encephalomyelitis (EAE), we characterized the role and function of MCAM in immune cell migration to the brain. Results: We demonstrate that MCAM is expressed on BBB endothelial cells, in vitro and in situ, and that MCAM expression can be up-regulated with inflammatory cytokines in vitro. Since MCAM's known ligand is MCAM itself, we analyzed MCAM expression on peripheral blood leukocytes from healthy human donors and MS patients. MCAM is detected on a subset of activated memory CD4+ and CD8+ lymphocytes and the proportion of MCAM+ T cells appears to be higher in MS patients compared with controls. Furthermore, in vitro microscopy studies suggest that MCAM plays a role in lymphocyte adhesion and diapedesis. Conclusions: Our preliminary data provides evidence that MCAM is expressed by both the BBB and the immune cells and suggests that MCAM is potentially involved in MS lesion formation. 
University of Genoa, Genoa, Italy
Background: Inflammatory and degenerative changes in MS normalappearing white matter (NAWM) are now recognized to be an important feature of the disease, especially in the progressive phases of MS. The features of the diffuse inflammatory changes in MS NAWM are currently still being defined. Objective: The aim of this study was to better characterize the immune mechanisms underlying the pathologic changes in MS NAWM, evaluating features such as tissue inflammation, presence of plasmacells and lymphocytes, axonal damage, expression of vascular adhesion molecules, presence of functional APCs, immunoglobulin deposition, and presence of blood-brain barrier damage. Methods: This study was performed on whole coronal sections of 15 brains of MS patients, as well as on 3 control brains and on 8 amyotrophic lateral sclerosis brains (a degenerative, noninflammatory neurological disease), using immunohistochemistry to detect significant antigens (MBP, HLA-DR, CD68, fibrinogen, IgG, VCAM-1, neurofilaments, beta-APP, CD83, CD86, CD3, CD20, CD138, ICAM-1). Results: Diffuse expression of vascular adhesion molecules, such as VCAM-1, was detected on most vessels in MS NAWM, without overt signs of apparent blood-brain barrier disruption as shown by fibrinogen immunohistochemistry. Presence of microglial activation, perivascular lymphocyte infiltration, perivascular macrophages and mature (CD83+) dendritic cells was observed consistently in the NAWM in most MS brains. Signs of axonal damage (deformed and thickened axons, beta-APP positive axonal spheroids) were observed in the NAWM in most MS cases. Immunoreactivity for IgG was frequently observed on dystrophic axons in MS NAWM. Conclusions: Diffuse expression of vascular adhesion molecules and presence of mature dendritic cells are commonly observed in MS NAWM, in parallel with diffuse microglial activation, perivascular lymphocyte infiltration and axonal damage, and also in cases of MS with a long-standing progressive course. Neurodegeneration in progressive MS could be driven by diffuse inflammatory changes in NAWM.
investigate inflammatory NAWM pathology in vivo, using USPIOenhanced quantitative MR imaging. Methods: Sixteen MS patients (8 relapsing-remitting (RR) and 8 primary-progressive (PP) MS cases) and 5 healthy control subjects were included. Using a flip-angle array, B1-corrected T1-maps were generated before and 24 hours after USPIO (SHU555C) injection. T1 histogram characteristics of automatically segmented white matter (WM) masks, from which lesions were excluded, were compared between both time points, as well as T1 characteristics of regions of interest (ROIs) placed manually in the NAWM. Results: Both NAWM ROI and histogram analyses resulted in significant T1 shortening after USPIO injection in MS patients (p<0.01; Wilcoxon signed-rank test), but not in healthy controls (p=0.68). This result seemed to be driven mainly by the RRMS cases, which showed significant USPIO-enhancement in subgroup analyses as well (p<0.05), whereas PPMS cases did not (p=0.17). Conclusions: We show that the widespread inflammatory activity in MS NAWM, which has so far only been observed in post mortem studies, can be detected in vivo using USPIO. As this ongoing inflammation may play an important role in the development of irreversible disability, further studies may now focus on relating this diffuse inflammation to clinical disease activity and treatment efficacy. Supported by: Dutch MS Research Foundation, Voorschoten, The Netherlands, grant 05-358-c.
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Identification of a factor inhibiting nucleocytoplasmic transport and differentiation within preserved oligodendrocyte precursor cells in multiple sclerosis: a possible cause for remyelination failure Jin Nakahara Background: Adult CNS retains its ability to spontaneously repair myelin after demyelinating insults. In MS, however, such remyelination is rather inconsistent and often fails, leading to sustained neurological deficits in patients. Oligodendrocyte precursor cells (OPCs) persist near the demyelinated axons arising in MS, but inefficiently differentiate into oligodendrocytes and remyelinate them, of which pathogenesis remains elusive. A recent study revealed that axonal Contactin acts as a positive ligand for oligodendroglial Notch1 receptor to induce differentiation and myelination. Expression of Contactin on axonal surfaces is dependent upon neuronal electrical activity whereas axonal damage is observed in MS lesions. Objective: We have initially hypothesized that injured axons in MS fail to present Contactin, which may contribute to remyelination failure. Methods: Axoglial Contactin-Notch1 signaling was tracked in situ using 10 autopsied MS brain materials containing chronic demyelinated lesions. Results: Instead, we found that Contactin is saturated on many demyelinated axons, Notch1-positive OPCs accumulate in Contactin-positive lesions, and the receptor is engaged as shown by cleavage to Notch1-intracellular domain (NICD), indicating that the initiation of axoglial signaling is not altered in MS. However, nuclear translocalization of NICD, required for myelinogenesis, is substantially reduced in these OPCs. NICD and related proteins carrying nuclear localization signals are associated with the nuclear transporter Importin β, but are nonetheless trapped in their cytoplasm. We have identified an ectopic expression of TIP30, a direct inhibitor of Importin β, co-localized with cytoplasmic NICD-Importin β complex in these OPCs. Over-expression of TIP30 in OPC cell lines in vitro resulted in cytoplasmic entrapment of NICD and arrest of differentiation upon stimulation with Contactin-Fc. Conclusions: Our observations suggest that an intrinsic nucleocytoplasmic transport blockade by TIP30 within OPCs may be involved in the pathogenesis of remyelination failure in MS.
Plenary Session 1 ACTRIMS/CMSC * Donald Paty Memorial Lecture
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The changing frame of multiple sclerosis over the centuries T. Jock Murray Dalhousie University, Halifax, Nova Scotia, Canada Dr. Donald Paty was a major participant in virtually every area of advancement in the understanding and treatment of multiple sclerosis (MS) in the last half century. His pioneering concepts for a multidisciplinary research clinic, early work on classification, neuro-imaging, clinical trials and standards for MS were recognized by the first Dystel Prize for MS from the National Multiple Sclerosis Society and the Scheinberg Award from the Consortium of MS Centers, of which he was a founder. Dr. Paty was very interested in the history of the disease to which he contributed so much, and helped edit the initial draft of my book on the history of MS. I am privileged to present this lecture that honors my late friend of 35 years. Although patient diaries and medical reports provide evidence of MS before the disease was named by Charcot in 1868, after he and colleagues demonstrated the features of the disease, cases were diagnosed around the world. Little changed in that characterization for the first 50 years. Since then the concepts of pathophysiology, pathology, etiology, epidemiology, immunology, genetics, environmental factors, social implications and therapies have continually changed. Initially thought to be rare, by 1900 it was recognized as one of the most common debilitating neurological diseases. Therapies abounded despite the observations of clinicians that they probably did not alter the outcome of the disease. Treatments were adapted from other disorders such as syphilis, even though some worsened their symptoms. By the 1930s a list of 158 therapies for MS was compiled by Brickner, and it was felt that at least half of the patients benefited from the treatments. Waves of enthusiasm characterized a rapidly changing series of therapies in the mid 20th century, such as arsenic, anticoagulants, vaccines, fever therapy, histamine desensitization, vasodilators, antibiotics, diets and many popular fad cures. Reviews by Russell Brain (1931), George Schumacher (1950) and Paul Thygesen (1953) were generally negative about these therapies. Only with the initial studies of ACTH by Randt and Merritt in the USA (1950), Henry Miller in Newcastle (1961) and others, and finally the American trial by Augustus Rose in the United States (1970) was there some evidence of a therapeutic effect at least on acute relapses of MS. The era of randomized clinical trials in MS had begun. The modern age of therapy for MS began in the 1990s when years of work led to the development of four immune modulating therapies that altered the outcome of the disease for the first time. Now MS is one of the major areas of neurological research, bringing new understanding and new approaches to therapy. All of this has created a strong sense of hope in the MS community, a striking change from the era when it was thought to be a hopeless, untreatable disease. What has a historical study of MS taught me? That there is a strong therapeutic imperative in both physicians and patients. That the therapeutic imperative can blind physicians to benefit and harms. That when evidence and belief clash, belief often wins. That credit goes to the one who makes something known, not to who was first. That physicians can lead change but also can resist it. That important information can be found and lost, and found again. That discovery has a context, and can fizzle if outside the prevailing paradigm. That research is limited by different factors at different periods. That methods of discovery have dramatically changed over the century. That advances are made by small steps, and only rarely by great discoveries. And finally, that the greatest strides are made by collaboration -collaboration between physicians and patients, physicians and scientists around the world and with MS Societies and other supporting agencies. Bruce F. Cummings, writing about his personal struggle with MS in 1919, concluded it would be nice if a physician, 'one of these days, were to gallop up hotspur, tether his horse to the gait post and dash in waving a reprieve -the discovery of a cure!' It could occur at this meeting, but more likely we will see the numerous and exceedingly important incremental steps that lead towards that day. Multiple sclerosis (MS) is generally regarded as an inflammatory demyelinating disease of the central nervous system. There is increasing evidence that MS also has a neurodegenerative component which appears to be the major cause of disability of MS patients. One of the major questions in MS pathogenesis is whether this neurodegenerative component occurs as a consequence of early inflammatory demyelination specifically in the progressive disease stage or whether neurodegeneration is an early phenomenon in MS lesions. There is increasing evidence from morphological studies that axonal pathology such as axonal transections or acute axonal damage occurs early in MS lesions but also in areas that are described as normal appearing white matter. This is supported by recent magnetic resonance imaging (MRI) and magnetic resonance spectroscopic (MRS) studies. In addition, cortical pathology with demyelination and neuroaxonal damage also appears to be an early event in lesion pathogenesis and contributes to the permanent clinical deficit of the patients. The presentation will give an overview on the current knowledge and evidence for primary neurodegenerative events in the pathogenesis of MS lesions. Neuropathological studies of multiple sclerosis (MS) have shown reduced numbers of axons in normal-appearing white matter (NAWM) attributed to Wallerian degeneration of axons within white matter plaques. This is also manifest as tractal degeneration in MS spinal cord. Inflammatory cells in close proximity to degenerating axons in MS are considered to be mediators of axonal destruction. Components of the immune/inflammatory response, shown to have detrimental morphologic or physiologic effects on neurons/axons, have been documented by immunohistochemistry or molecular biological techniques in the MS plaque. These include CD4 lymphocytes and their proinflammatory and immunomodulatory cytokines, CD8 cytotoxic T-cells, activated microglia, macrophages (with proteases and other enzymes), matrix metalloproteinases, chemokines, antineuronal antibodies, complement, calpains, glutamate, cyclooxygenase-2, nitric oxide (NO), peroxynitrite and free radicals. NO is particularly toxic to demyelinated axons. Inflammation has also been detected in NAWM, where similar neurodegenerative factors may be operative. Degeneration of neuronal somata and neurites has been attributed to the effects of activated microglia in gray matter. Blood-brain barrier dysfunction in MS plaques and NAWM, secondary to the inflammatory infiltrates, allows the introduction of previouslyexcluded systemic neurotoxins into the CNS parenchyma. Demyelination itself is associated with secondary changes in axons, including dephosphorylation of neurofilaments and reduction in axonal diameter. The redistribution of sodium channels along the demyelinated axolemma, evident in immunohistochemical studies, results in excessive energy demands on the axon and increased axoplasmic sodium concentration, the latter triggering the sodiumcalcium exchanger leading to toxic levels of intra-axonal calcium. The insertion of calcium channels in the demyelinated axolemma has a similar effect. In summary, histopathologic, immunohistochemical and molecular studies of plaques and non-plaque parenchyma indicate that neurodegeneration in MS may be secondary to the effects inflammation and demyelination. Background: Four patterns of demyelination have been described in active demyelinating lesions of multiple sclerosis (MS) patients that were biopsied shortly after disease onset. These patterns were suggested to represent heterogeneity of the underlying pathogenesis. Objective: The aim of our study was to determine whether lesion heterogeneity also exists in an unselected collection of autopsy material from patients with established MS. Methods: All post-mortem MS brain tissue available in the VU medical center was assessed for the presence of active demyelinating lesions using magnetic resonance imaging (MRI)-guided sampling and immunohistochemistry. Tissue blocks containing active demyelinating lesions -defined by the presence of activated macrophages containing intracellular myelin proteins (63 tissue blocks from 27 MS patients) -were evaluated for the presence of complement and antibody deposition, oligodendrocyte apoptosis, differential loss of myelin proteins and hypoxia-like damage using histology, immunohistochemistry and confocal microscopy. Active demyelinating lesions were compared with active (non-demyelinating) and inactive lesions. Results: Deposition of antibodies and activated complement components was consistently associated with active demyelination. Antibodies and complement colocalized with myelin proteins in phagocytic vesicles in macrophages. This pattern was observed in all tissue blocks containing active demyelinating lesions; lesion heterogeneity between patients was not found. Preferential loss of myelin proteins, extensive hypoxia-like damage and oligodendrocyte apoptosis were absent or very rare in our tissue sample. Conclusions: We conclude that the immunopathological appearance of active demyelinating lesions in established MS is uniform. Initial heterogeneity of demyelinating lesions in the earliest phase of MS lesion formation may disappear over time as different pathways converge in one general mechanism of demyelination. Consistent presence of complement, antibodies and Fcγ receptors in phagocytic macrophages suggests that antibody-and complement-mediated myelin phagocytosis is the dominant mechanism of demyelination in established MS. 
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Evidence for secondary neurodegeneration in multiple sclerosis
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The progression of brain atrophy is similar in drug-free MS subtypes: A longitudinal study of a large patient population Antonio Giorgio 1 multiple sclerosis (MS). However, differences in atrophy rates between MS patients with different subtypes and disease stages are not known. Objective: To evaluate differences in brain atrophy progression in a large population with different forms of MS and free from disease modifying treatment during follow-up. Methods: We analysed existing data sets of MS patients who either were in the placebo arm of clinical trials or were not taking any disease modifying therapy. The total of 964 patients were classified into clinically isolated syndromes (CIS, 16%), relapsing-remitting (RR, 60%), secondary progressive (SP, 15%) and primary progressive (PP, 9%). Expanded Disability Status Scale (EDSS) score was assessed at baseline and end of study. The mean follow-up was 18 months (range: 12-68). Conventional T1-weighted MR images (two scans per patient) were used to quantify brain volume changes over time. The analysis was performed using the SIENA method. The results were correlated with clinical-demographic information. Results: Annualized percent brain volume change (PBVC/y) was -0.40±0.47 in CIS, -0.49±0.65 in RR, -0.64±0.67 in SP, -0.56±0.55 in PP. PBVC/y of CIS was significantly different from that of SP after correcting for age and gender (p <0.01). This difference disappeared when data were also corrected for the baseline brain volume. EDSS at baseline and annualized EDSS changes weakly correlated with PBVC/y in the total population (r= -0.15 and r= -0.10, respectively; p<0.005), but did not correlate in MS subtypes. Conclusions: In a large group of MS patients free from specific drug treatments, annualized brain volume changes had similar rates at early and late disease stages. This suggests that mechanisms leading to brain atrophy act steadily during disease evolution. In the short term, brain volume loss is weakly associated with disability progression.
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Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial Douglas L. Arnold, Sridar Narayanan, Samson Antel, for the PreCISe MRS Ancillary Study Group.
NeuroRx, Montreal, Quebec, Canada
Background: The importance of neurodegeneration as the substrate of irreversible disability in multiple sclerosis (MS) is being increasingly appreciated. Neuro-axonal integrity can be assessed in vivo by measuring the concentration of N-acetylaspartate (NAA), which is synthesized exclusively by neuronal mitochondria. Objective: To determine whether glatiramer acetate (GA) could slow or reverse the expected decline in NAA over time in patients with CIS. Methods: We performed proton magnetic resonance spectroscopy (MRS) in a subgroup of patients participating in a large phase III, multicenter, randomized, placebo-controlled trial of GA for CIS (PreCISe). Spectra were acquired yearly from a single voxel centered on the corpus callosum of 34 subjects enrolled at 10 clinical sites in seven countries (TR 2000, TE 272, voxel size 50mmx70mmx18mm). Patients terminated at the time of relapse. Results: Paired changes in NAA (relative to creatine) differed significantly between patients treated with GA (+0.14, n=11) compared with placebo (-0.33, n=9, p=0.03) at 12 months. These changes tended to be maintained at 24 months (GA (n=6): +0.17, placebo (n=3): -0.23, p=0.15). Changes in contrastenhancing lesion frequency, new T2 lesion frequency, T2 lesion volume, brain volume, and EDSS were not significant in this small subgroup of patients. Conclusions: In this phase III, randomized, placebo-controlled trial of GA therapy for patients with CIS, patients who received GA showed improvement in their cerebral neuroaxonal integrity relative to patients treated with placebo, who showed the decline expected from natural history studies. MRS was more sensitive than atrophy measurements, presumably because the neuroaxonal injury was still largely sublethal at this early stage of disease. This is the first class A evidence of neuro-axonal protection by disease modifying therapy for MS using the pathologically specific neuroaxonal marker, NAA. Supported by: Teva.
Parallel Session 2 Neuromyelitis optica (NMO)
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Clinical pathological spectrum of NMO 
Hans Lassman
Center for Brain Research, Medical University of Vienna, Vienna, Austria Neuromyelitis optica (NMO) was originally defined as an acute monophasic inflammatory demyelinating disease affecting the optic nerves and the spinal cord. Recently an NMO specific autoantibody response was discovered, which is directed against the astrocytic water channel aquaporin 4 (AP-4). Patients with NMO and circulating AP-4 antibodies in general present with longitudinally extensive lesions in the spinal cord and optic neuritis. More recent systematic clinical studies revealed that NMO frequently takes a relapsing-remitting disease course and lesions in the central nervous system may also be seen in other regions than the spinal cord and optic nerves. In pathology NMO lesions are characterized by inflammation and primary demyelination, which, however, is generally associated with severe tissue destruction. In contrast to classical MS lesions, active NMO lesions contain large numbers of granulocytes and in particular of eosinophils. Inflammation is most prominent in perivascular areas, leading to severe perivascular damage and fibrosis. Complement deposition is prominent and activated complement is seen in a rosette-like pattern nearly exclusively on astrocytes. This is associated in fresh lesions by extensive loss of astrocytes and their processes and a complete loss of aquaporin reactivity in the affected areas. Lesion topography in the brain and spinal cord of NMO patients follows the distribution of AP-4 in the central nervous system. Thus areas with high AP-4 expression are more likely to be affected than those with low AP-4 expression. High expression of AP-4 is also seen in circumventricular organs and this explains a dominance of pathological alterations in these areas. In rare cases, however, the distribution of lesions may be atypical, for instance presenting with a single forebrain white matter lesion in the absence of spinal cord or optic nerve involvement. Such cases may present problems in differential diagnosis.
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Clinical features of NMO in Latin American populations Marco A. Lana-Peixoto
Neurology and Ophthalmology. CIEM MS Research Center, Federal University of Minas Gerais Medical School, Belo Horizonte, MG, Brazil
Devic's neuromyelitis optica (NMO) is an immuno-mediated demyelinating disease which predominantly occurs in non-Caucasians. As Latin American populations have strong authochthonous and African ascendancy study of NMO in the continent may provide relevant information on the role of race on its distribution and clinical phenotypes. Different series have been published from Mexico, Caribbean Basin, Argentina and Brazil. A study from Mexico City (Rivera et al., 2008) disclosed 34 cases of NMO (23 monophasic and 11 relapsing) and 390 cases of multiple sclerosis (MS). All NMO patients were Mestizos, 71% were females and the median age at diagnosis was 36 years. In Martinique, Cabre et al. described 62 cases of MS and 17 cases of NMO in French Afro-Caribbeans. All NMO patients were females. The mean EDSS was 2.2 for NMO and 7.1 for MS patients. In a recent study (Merle et al. . In a poster at this meeting we describe 265 NMO patients from South-eastern Brazil (90% relapsing; 212 females; age at onset 5 to 71 years; median DSS 4; disease duration up to 60 years). In this study we observed that disability in NMO, as opposite to MS, is related to attacks more than to disease progression.
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Treatments for NMO Dean Wingerchuk
Neurology, Mayo Clinic, Scottsdale, Arizona, USA Neuromyelitis optica (NMO) diagnosis requires occurrence of optic neuritis and acute myelitis. Diagnosis is supported by detection by MRI of longitudinally extensive transverse myelitis (LETM), normal or nonspecific white matter lesions on brain MRI at disease onset, and seropositivity for NMO-IgG. The NMO-IgG autoantibody (antiaquaporin-4) facilitated the description of a wider spectrum of NMO disorders which include relapsing LETM, LETM associated with NMOIgG, relapsing isolated optic neuritis, and Asian optic-spinal MS, among others. Congruent clinical, laboratory, and immunopathological evidence strongly implicates humoral autoimmune mechanisms in NMO pathogenesis. NMO spectrum disorders usually follow a relapsing course. Relapses account for almost all disability associated with NMO because, in contrast to typical MS, a secondary progressive course is uncommon. Therefore, aggressive treatment and prevention of individual relapses represents the cornerstone of current therapeutic recommendations. For acute relapses, immediate intervention with intravenous corticosteroids is standard practice; rescue plasmapheresis is employed for severe, progressive, steroid-refractory events. The role of adjunctive general immunosuppressive agents such as cyclophosphamide is being explored. Based on current understanding of NMO pathogenesis and observations that standard MS diseasemodifying therapies may be ineffective or even exacerbate NMO, immunosuppressive therapy is recommended for relapse prevention. There are case reports or series suggesting benefit of agents such as azathioprine, mycophenolate mofetil, mitoxantrone, cyclophosphamide, methotrexate, IVIG, and rituximab. Patients with established NMO require long-term therapy; NMO-IgG seropositive patients with a first attack of LETM should also be treated for attack prevention because they are at high risk for relapse or conversion to NMO. Current therapeutic evidence is limited to observational studies and determination of optimal therapeutic drugs and strategies will require randomized controlled therapeutic trials.
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Effects of B-cell depletion on T-cell subsets and function in neuromyelitis optica Claude P. Genain Background: Rituximab (RTX) improves clinical outcome in neuromyelitis optica (NMO). The mechanisms for this effect are not known. Objective: To assess the immunological impact of treatment with RTX in NMO. Methods: Ten out of 12 subjects completed the study and were observed for a period of 94 weeks. RTX was administered in two cycles: 1g intravenously at weeks 0 and 2, repeated at weeks 36 and 48. Patients did not receive immuno-suppression within 3 months of enrolment, or corticosteroids except 10mg of dexamethasone with RTX. Samples of venous blood were obtained at baseline (prior to the first RTX cycle, day 0), and at regular intervals thereafter, to perform quantitation of lymphocyte subsets by FACS, assay of T cell activity after stimulation with PHA, and OKT3 (non B cell-dependent T cell reactivity), MOGaa1-125, and linear peptides of MOG (B cell dependent T cell activation). Concentrations of IL-2, IL-4, IL-10, IL-12 (p70), IFNγ, and TNFα after the different stimulation conditions were measured using Bio-plex Cytokine assay kits (BioRad). Results: 1. B-cell depletion was achieved in all patients. 2. T-cell proliferative responses to PHA were markedly suppressed and this effect was sustained. By 24 weeks, T-cell proliferation to PHA and OKT3 was suppressed by 94% (P=0.017) and 78% (P=0.028), respectively. 3. T cell proliferative responses against MOG were present at baseline in 1/3 of the patients (4/12), and abolished by RTX (-92%, P=0.03), unlike reactivity to linear MOG peptides. 4. Cytokine secretion by both PHA-stimulated and MOG-stimulated T cells was abolished by RTX. Conclusions: 1. The marked and prolonged suppression T cell reactivity against MOG suggests that inhibition of presentation of whole antigen following B-cell depletion is a major MOA for RTX. 2. There was no Th1 to Th2 bias (immune deviation) 3. Suppression of T-cell functions has implications for monitoring immune function in context of long-term B-cell depletion. Background: Antibodies against aquaporin-4 (AQP4), a water channel particularly expressed on perivascular astrocytic podocytes, are proposed as a marker for the diagnosis of neuromyelitis optica (NMO). However, a consensus on seroprevalence and the optimal detection method has not yet been reached. Objective: We set up five different assays. Two of them were capable of detecting perivascular IgG reactivity on brain tissue by immunofluorescence (NMO-IgG). The other three assays have been set to specifically detect anti-AQP4 antibodies: immunofluorescence and flow cytometry on AQP4-expressing cells, and a radioimmunoprecipitation assay. Methods: We assessed sensitivity and specificity of the different assays by examining sera of 33 NMO patients, 13 patients at high risk to developing NMO (hrNMO), 6 patients affected by acute partial transverse myelitis (APTM), 20 patients with multiple sclerosis (MS), and 67 age-and sex-matched healthy controls. Results: As expected, we found that the presence of serum NMO-IgG and anti-AQP4 reactivity is almost exclusively restricted to patients with NMO and hrNMO. Seroprevalence and sensitivity ranged from 30 to 47%, depending on the assay. Specificity ranged from 95 to 100%. In comparing results obtained in the five assays we noticed lack of concordance in some samples. However, sensitivity increased to over 60% if all assays were used in combination. Conclusions: Detection of NMO-IgG or anti-AQP4 antibodies may represent, in the very near future, a valuable tool to assist neurologists in differential diagnosis between NMO, hrNMO, APTM and MS. The current lack of a gold standard to detect anti-AQP4 antibodies implies the necessity to standardize the detection of these antibodies.
Parallel Session 3 Brain plasticity and repair
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Myelin repair in the central nervous system: role of guidance molecules Catherine Lubetzki, Gabriele Piaton, Anna Williams, Sarah Moyon, Imane Moutkine, Aurelien Kerever, Hisataka Tanaka, Carlos Parras, Marie Stéphane Aigrot
Hôpital de la Salpêtrière, UPMC, Paris, France
Many different mechanisms are leading to myelin repair failure in multiple sclerosis (MS). In some lesions, demyelination coexists with the presence of oligodendroglial precursor cells within the lesion, suggesting the existence of inhibitors of oligodendroglial differentiation or maturation. Some of these inhibitors, either axonal or oligodendroglial, have recently been identified. Alternatively, other demyelinated lesions are characterized by an oligodendroglial depopulation. This might be related to an exhaustion of the oligodendroglial pool related to successive attacks of demyelination. Alternatively, this lack of oligodendroglial cells may correspond to the defect of recruitment of oligodendroglial progenitors (OPC) to the demyelinated lesion, possibly related to a dysregulation of guidance molecules. In this context, we have recently shown that the expression of semaphorins 3A and 3F, which act as OPC guidance cues during development, is altered in MS tissue. Semaphorins 3A and 3F are overexpressed by glial cells within inflammatory demyelinating lesions, and some oligodendroglial cells in the surrounding white matter express their receptors. In addition, semaphorins 3A and 3F are up-regulated in cortical neurons in the gray matter. We have reproduced this expression pattern by inducing demyelinating lesions in the rat cortico-spinal tract. We suggest that semaphorin overexpression after a demyelinating event could influence OPC migration, hence remyelination efficacy. To get further insight into this hypothesis, we are currently analyzing adult OPC response towards Sema 3A or 3F, by evaluating the migration of OPC isolated by FACS from adult transgenic MASH-1 GFP or PDGF-R-GFP mouse brains. In parallel, we evaluate in vivo, in experimental spinal cord demyelination, the influence on OPC recruitment and remyelination of a lentiviral-mediated overexpression of semaphorin 3A or 3F. These results could open promising avenues for therapeutic strategies in MS, aimed at favouring myelin repair.
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Axo-glial interactions: role of transporters and glutamate receptors Peter Stys
Clinical Neurosciences, Hotchkiss Brain Institute., University of Calgary, Calgary, Alberta, Canada MS histopathology exhibits not only demyelination of central axons, but also widespread axonal degeneration. This axonopathy is particularly brisk in acute plaques, but is also seen in chronic seemingly inactive lesions and also in normal appearing white matter in MS patients. Axonal damage may be the most important determinant of progressive and irreversible clinical disability in this disease, yet the pathogenesis is unknown. Recent work has indicated that mitochondrial compromise and reduction of ion transport via the ubiquitous Na-Ka-ATPase may be key features leading to cellular damage in MS. Failure of ion pumping in compromised axons leads to Na overload and depolarization. As a result, several Na-coupled and electrogenic ion and molecular transporters are stimulated to operate in reverse modes, transporting substances in inappropriate directions leading to damaging accumulation (eg. Ca loading via Na-Ca exchangers, transmitter release via reverse transport). Recently, studies have identified glutamate receptors on axons and oligodendrocytes, their processes and even inner and outer loops of mature myelin. Among them, NMDA receptors require both glutamate and glycine as obligatory coagonists. Na-coupled glutamate and glycine transporters, driven in the transmitter efflux mode by cellular Na loading and depolarization, promote excessive activation of receptors and Ca entry into compartments already unable to adequately buffer ionic loads. Thus, excessive glutamate and glycine release, leading to receptor over-activation, represents a novel and potentially very important mechanism of injury to oligodendrocytes and the myelin sheath. In contrast, NMDA receptors do not play an important role in injury to the axon cylinder per se. Instead, internodal "nanocomplexes" containing AMPA or kainate receptors, Ca channels and nNOS are stimulated leading to ryanodine receptor activation and release of Ca from axonal stores. This increasingly rich complement of signaling pathways in central myelinated axons and glia may be amenable to pharmacomodulation in MS and other disorders of central white matter.
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New observations on the mechanism of myelin wrapping David Colman
Neurology & Neurosurgery, Montreal Neurological Institute, Montreal, Quebec, Canada
The early electron microscopic observations by Betty Geren and others led to the hypothesis that the innermost turn of the myelinating glial cell 'crawled' around the axon, uniformly, laying down in its path the compact myelin sheath. This view has remained unchallenged since it was first proposed in 1954, but we find now that it does not hold up to careful scrutiny. We offer a new model for myelin sheath synthesis that involves as the major players the SchmidtLantermann incisures as well as the paranodal loops as local agents by which newly synthesized membrane lipids and proteins are incorporated and assembled into the forming myelin sheath. This model argues for an intensively active local synthesis of myelin sheath components which are readily and accurately assembled into a complete internode. Background: In the adult mammalian brain, multipotent and selfrenewing neural progenitor cells (NPCs) may generate new neurons, astrocytes and oligodendrocytes. NPCs may thus serve as a regenerative tool by which brain damage could be compensated. However, repair processes in response to inflammatory (and other) forms of brain injury are characterized by the failure of neuronal regeneration and the predominant occurrence of astrocytes (known as astrogliosis). Moreover, inflammation, which generates an oxidative milieu, has recently been reported to directly inhibit neurogenesis within the brain. Objective: To clarify possible molecular pathways underlying inflammation-mediated inhibition of neurogenesis and enhancement of astrogenesis in chronic autoimmune neuroinflammation. Methods: We systematically investigated the effects of redox modulation in neural stem cells in vitro and in vivo, as well as in the animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). Results: We found that subtle (non-toxic) oxidation suppressed proliferation of NPCs and directed their differentiation towards the astroglial lineage at the expense of the neuronal (and vice versa). Our findings indicate that oxidation plays an instructive role in directing uncommitted NPCs to differentiate towards the astroglial lineage by altering their 'default' development program. According to our data, Sirt1, a class III NAD+-dependent histone deacetylase involved in various cellular processes that comprise energy metabolism, transcriptional silencing, and DNA repair, mediates the observed redox effects, as mild oxidation in NPCs leads to increased Sirt1 deacetylase activity at the promoter of the proneuronal transcription factor Mash1. Furthermore, ongoing analysis of Sirt1 regulation in the course of EAE will be presented. Conclusions: Our results provide evidence for an as yet unknown metabolic master switch which has an impact on the fate of neural progenitors under inflammatory conditions. Background: While bone marrow derived mesenchymal stem cells (MSC) have been proposed for brain repair due to their multipotentiality, recent experimental data challenged their transdifferentiation capacity and suggested that they could modulate pathogenic immune responses. Objective: The aim of this study was to address the in vivo effects of MSC on neural cells inside the inflamed central nervous system (CNS) as well as on key T cell subsets infiltrating both in the lymphoid organs and in the CNS. Methods: We evaluated the MSCmediated effects in MOG-induced experimental autoimmune encephalomyelitis (EAE) by immunological, histological and molecular analysis of CNS specimens. Results: We showed that irrespective of the lack of MSC neural differentiation, MSC decreased axonal sufferance through the inhibition of astrogliosis and microglia activation and the upregulation of genes involved in the BMP and Notch pathways. In addition, upon isolation of T cells from the brain of EAEaffected mice we detected an increase of CD4+ FoxP3 + T regulatory cells and a decrease of IL-17 producing T cells compared with control EAE mice. Conclusions: Thus MSC may represent a valuable approach for the treatment of autoimmune diseases such as multiple sclerosis where tissue degeneration is associated with inflammation. Supported by: CARIPLO Foundation, Italian MS Foundation.
Parallel Session 4 Antibodies: from pathogenesis to treatment
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What is the evidence in humans that auto-antibodies to CNS antigens are pathogenic? Jeffrey L. Bennett
Neurology, University of Colorado Denver, Denver, Colorado, USA
Clinical, pathologic, and laboratory data have long implicated antibodies in MS pathogenesis. In some patients, a fraction of the immunoglobulin (Ig) in multiple sclerosis (MS) plaque, cerebrospinal fluid (CSF) and serum are human auto-antibodies against central nervous system (CNS) antigens. Although readily identified in affected individuals, the relationship between these auto-antibodies and clinical disease is specious. Historically, the predominant focus has been placed on human auto-antibodies against major myelin immunogens: myelin oligodendrocyte glycoprotein, myelin basic protein and proteolipid protein. While variations in assay design, differing control populations, lack of standardization, and limited numbers of subjects have hampered comparisons between investigations, cumulative data argue against the presence of high titer antimyelin antibodies in MS CSF and sera and demonstrate no definitive relationship between these antibodies and clinical outcomes. The confounding results have prompted researchers to search for auto-antibodies against alternative CNS protein, lipid, and carbohydrate moieties. Igs against CNS antigens such as ribonucleoprotein, α,β-crystallin, sulfatide, sphingomyelin, and galactocerebroside have been reported, but additional experiments are needed to confirm whether these novel targets are disease specific and pathogenic. Since molecular immunologic studies consistently demonstrate the presence of an antigen-targeted humoral immune response in MS patients, the continued search for pathogenic antibodies may require increasingly sensitive techniques that can identify low-abundance antigen. Interestingly, the recent success of B-cell depletion in the treatment of relapsing-remitting disease, which occurred in the absence of significant changes in Ig synthesis, has raised important questions regarding the role of antibody mediated pathogenesis in the short-term control of disease activity. Future investigations will need to determine whether the observed effects are secondary to the depletion of subpopulations of diseaserelevant antibodies and whether the observed clinical effects are maintained in the absence of reduction in intrathecal Ig. In contrast to earlier disease concepts of MS suggesting that pathogenic T cells were sufficient for full expression of the disease, it is now established that autoimmune B cells and humoral immune mechanisms also play major roles in mediating tissue damage. Current evidence indicates that diverse protein and lipid antigens are likely to be targets of humoral autoimmunity in MS. In MS, memory B cells, which cross the blood-brain barrier, are believed to undergo restimulation, antigen-driven affinity maturation, clonal expansion, and differentiation to antibody-secreting plasma cells within the highly supportive CNS environment. Clonally expanded populations of memory B cells and plasma cells are also present in MS lesions and in cerebrospinal fluid, and can be detected even at the onset of clinical symptoms. In a phase II trial in RRMS reported in 2007, Rituximab (Rituxan), a chimeric monoclonal antibody that targets CD20-positive B lymphocytes, reduced disease activity measured by MRI; secondary endpoints were also positive, including a reduction of clinical relapses. Suggestive efficacy was also observed in a phase 1 trial. In primary progressive MS, a phase II/III trial has been completed and preliminary results will be presented at this meeting. The beneficial effects in the RRMS anti-CD20 trials occurred within weeks of the initial infusion, indicating that a direct effect on B cellsand not on autoantibodies -was responsible. Interference with B cell trafficking is one presumptive mechanism of action. The duration of action was also longer than the period of B cell depletion, suggesting that repopulating B-cells were less pathogenic. In a larger sense, the discovery that B-cell depletion has an impact on MS biology represents a paradigm shift in understanding how the inflammatory phase of MS develops; the data shift our perspective on the cause of MS, and open up a new area of investigation which may lead to development of increasingly selective therapies against humoral immune system pathways. 
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Lipids as autoantigens and therapeutic immune modulators in multiple sclerosis
Background:
The targets of the autoimmune response in multiple sclerosis (MS) remain poorly understood. The myelin sheath comprises 70% lipids and 30% proteins. Objective: We hypothesize that lipids could represent important autoantigen targets in MS. Methods: We used our lipid array technology to profile lipid reactive antibodies in spinal fluid from individuals with MS versus other neurological disease controls. Array-identified lipids that showed increased autoantibody reactivity in MS individuals were administered to mice induced for experimental autoimmune encephalomyelitis (EAE), the prototypical animal model for MS. Results: Unexpectedly, 1-Palmitoyl-2-Glutaroyl-sn-Glycero-3-Phosphocholine (PGPC), an oxidized form of phosphatidyl-choline, prevented induction of and also treated established EAE. To understand the mechanism of action, we next tested two groups of PGPC derivatives: lipids with modified polar head groups or lipids with modified hydrophobic side chains. We found that an accessible phosphate head group, rather than a specific hydrophobic side chain, was necessary for binding to spinal fluid antibodies from individuals with MS. A select subset of these PGPC derivatives was able to treat ongoing EAE more effectively than PGPC. In vitro studies have shown that PGPC and these derivatives can specifically bind to T cells and suppress proliferation and the production of several pro-inflammatory cytokines including interferongamma, tumor necrosis factor, and IL-6. We are currently assessing the abilities of these lipids to modulate activated T cells through the binding of CD36 -a member of the class B scavenger receptor family, the activation of peroxisome proliferator-activated receptors (PPARs), and the induction of apoptosis. Conclusions: Auto-reactive antibodies present in the MS spinal fluid may not only target degrading myelin, but may also serve as negative regulators of inflammation. Further, the lipid targets of these antibodies may prove to be promising therapeutic immune modulators for autoimmune demyelination. 
Hot Topic 1 Costs and availability of MS treatments
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The impact of generics and biosimilars in interferons Victor Rivera
Neurology, Baylor College of Medicine, Houston, Texas, USA An important but often limiting factor to global accessibility of therapies in multiple sclerosis (MS) is the cost of biological immunomodulators. The advent of biosimilars (follow-on molecules) or 'generic' products, once the patent protection of the original (innovator) molecule has expired, theoretically, ideally, should reduce the acquisition price and provide an identical profile on efficacy and safety. Since 2004 'generic' beta interferons produced in Mexico, Argentina, and Korea, among others, have impacted significantly the international market share of the innovator products. Inadequate regulatory laws for biological medicines have favored their entrance into health systems. Regulatory stance remains under debate at EMEA, FDA, JPMA, ANVISA and others still without favorable decisions. Molecular similarity between beta interferons 1-b (innovator and follow-on) has been challenged by proteomic technology using mass spectroscopy. Cost containment from 'generics' has not been proven. Savings for consumers and health systems have been insignificant and prices even higher in some cases: i.e. Mexican Institute of Social Security, Occidental Medical Center formulary, biosimilar subcutaneous 44mcg betainterferon 1-a. The most notable characteristic of 'generic' interferons however (five beta 1-a and one beta 1-b products in the international market) is the absence of safety and efficacy data since phase I-IV reliable studies have not been performed (Class IV level of evidence; Recommendation 'U'). The pharmacological principles of compatibility, similarity and safety need to be established to satisfy patients, the neurological community and the World Trade Organization. Appropriate regulatory law changes for biosimilars including quality control, pharmacokinetics, immunogenicity, clinical and preclinical efficacy and safety (i.e. Mexican Article 222 bis, the Act H.R. 1038 and S.623 USA, and the Saudi Arabia Food and Drug Authority, to mention a few) are still in process. Until these definitions are accomplished 'generic' interferons for MS will remain as therapeutic proposals with their efficacy and safety still not supported by evidence.
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Costs and availability of multiple sclerosis treatments: impact on social security and public health systems in Latin America Arnoldo Soto
Neurology, Hospital Domingo Luciani, Caracas, Miranda, Venezuela
The economic impact of multiple sclerosis (MS) must embrace the cost of diagnosing the disease, treating the disease with disease modifying drugs (DMD), and treating relapses and complications including rehabilitation, psychological and cognitive dysfunction. In a survey conducted by the National Multiple Sclerosis Society (USA) in 1994 the annual cost of MS was over $34,000 per person. In Canada the annual costs were $7,596 at Expanded Disability Status Scale (EDSS) 1 and $33,206 at EDSS 6. An economic evaluation of MS showed the total three month cost was: in France, US$1,928 to US$5,678; in Germany, US$2,772 to US$5,701; in the UK, US$5,125 to US$14,622. The situation in Latin America is different. The use of disease-modifying drugs (DMDs) is not only related to the 'medical indication'. Most patients must pay for their medications and few patients are covered by private insurances. In few countries does the Social Security Service cover the treatments and not all of the DMDs are always available. Glatiramer acetate is prescribed in Argentina, Brazil, Mexico, Paraguay and Venezuela. A survey conducted by LACTRIMS in San Diego's CMSC in 2003 showed that only 9 to 20% of MS patients in Latin America received treatment with DMD. Immunosuppression and steroids are usually the most used treatment for MS in Latin America. The annual cost of diagnosing and treating MS in Latin America is: Costa Rica, US$7,200-10,800; Argentina, US$17,000; Honduras, US$14,000; Mexico, US$4,080,000 (long-term use of Inf B and treating relapses), Panama, US$12,000-14,400; Paraguay, $17,200, and Venezuela, US$25,500. Indirect cost is not included. No information is available in most countries. The cost for rehabilitation, treatment of spasticity, bladder and bowel disorders, cognitive dysfunction, sexual dysfunction and neuropathic pain is unknown. Finally, also unknown is the potential impact on the health systems with use of biosimilars in Latin America. 
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Autologous stem cell transplantation in multiple sclerosis
Neurology, Medical School of Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil
Background: The basis for autologous stem cell transplantion (ASCT) in multiple sclerosis (MS) is: MS has an autoimmune pathogenesis; ASCT can reverse the experimental allergic encephalitis; MS patients treated with ASCT for concomitant diseases get better; the prognosis of a contingent of MS patients is bad despite the use of immunomodulators. Objective: To report the preliminary results of ASCT for the treatment of MS. Methods: Inclusion criteria: age between 18 and 60 years old; patients getting worse despite the use of immunomodulators; Expanded Disability Status Scale (EDSS) between 3 and 6.5. Exclusion criteria: systemic infectious diseases; chronic lung, heart, kidney or hepatic diseases, and pregnancy. Stem cells are mobilized from the bone marrow to circulation after administration of 50mg/kg IV cyclophosphamide and granulocytic growth factor. At least 200 000 000 stem cells are collected by leucaphoresis, criopreservated and infused together with anti-timocytic globulin, after the conditioning regimen (200mg/kg/IV cyclophosphamide). Stabilization or improvement in the EDSS scale, reduction of relapsing and reduction of inflammation at the RM throughout 5 years of follow up are the final objectives of the procedure. Results: Twenty seven patients were treated with ASCT. The median time of follow up was 1 year and 6 months (range: 5 months to 3 years). Diarrhea, urinary infections, pneumonia and hair loss were the more important collateral effects of cyclophosphamide. No patient died. The EDSS of 21 patients was stabilized or reduced. For six patients the EDSS rose by 0.5 to 2.0 points. The overall number of new RM lesions was reduced considering the follow-up period and the two previous years before the ASCT. RMI volumetry from seven patients 1 year after the ASCT compared with controls showed less atrophy. Conclusions: Although the follow-up time is as yet short, the preliminary results of this open trial indicate that ASCT can be an alternative for treating MS and support the continuation of the study.
Hot Topic 2 Genomics and proteomics in understanding MS
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Do different disease courses display specific genomic features? Jonanthan Haines
Center for Human Genetics Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA Multiple sclerosis (MS) has long been known to have a strong genetic component based on the results of twin, sibling, adoption, and other genetic epidemiological studies. However, the genetic architecture of MS has largely eluded dissection. While association with specific alleles of the MHC has been known for over 30 years, identifying and confirming other associated genetic variation has not been forthcoming. One problem that can significantly hinder detection of associations is genetic heterogeneity, which may be mirrored in clinical heterogeneity. Recent advances in genomics are finally shedding light on MS genetics, with the confirmed association of variation in the IL7R and IL2R genes with MS. However, these associations have been in datasets dominated by relapsing-remitting MS, and specificity to disease course and severity has not been fully explored. There have been numerous reports of genetic associations to a specific disease course or disease severity (e.g. osteopontin, the MHC, apolipoprotein E, and toll-like receptors), but these effects have not been consistently replicated. The power of new genomic technologies promises resolution of these questions provided that adequate sample sizes are available for analysis.
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Proteomics and transcriptional profiling in understanding the pathogenesis of multiple sclerosis Lawrence Steinman
Neurology, Stanford University, Stanford, California, USA I shall review our studies on transcriptional profiling of defined multiple sclerosis (MS) lesions. I shall highlight a trio of proteins involved in relapse and remission: a4b1 integrin, osteopontin, and aB crystallin. I shall also highlight the role of molecules of the coagulation cascade in MS relapses.
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Altered microRNA expression in lymphocytes of relapsingremitting multiple sclerosis patients Raija L. Lindberg, Francine Hoffmann, Jens Kuhle, Matthias Mehling, Ludwig Kappos
University Hospital Basel, Basel, Switzerland
Background: MicroRNAs (miRNAs) are small 20-24 nucleotide, noncoding RNAs that post-transcriptionally regulate gene expression in various physiological processes, including hematopoiesis, cell differentiation, proliferation and apoptosis. Emerging evidence suggests the involvement of miRNAs in inflammatory and immune-mediated disorders, e.g. psoriasis, rheumatoid arthritis and systemic lupus erythematosus. However, nothing is known about miRNA expression in multiple sclerosis (MS). Objective: Our aim in the present study was to analyze miRNA expression profiles in lymphocyte sub populations in relapsing-remitting MS (RRMS) patients. Methods: Peripheral blood mononuclear cells (PBMCs) of untreated RRMS patients in remission and healthy volunteers (HV) were isolated with Ficoll gradient. CD4+ and CD8+ T-cells and B-lymphocytes were separated with anti-Biotin MicroBeads (Miltenyi Biotec). Total (including micro-) RNA was isolated with miRNA Isolation kit (Qiagen), and RT-PCR based, human microRNA panels, including 365 targets, were used (Applied Biosystems). Results: Distinct patterns of miRNA expression were found in CD4+ and CD8+ of RRMS patients compared with those of HVs. Five out of 10 differentially expressed miRNAs in CD4+ cells belong to the miR-17-92 cluster, i.e. miR-17-5p, 19a/b, 20a and 92. The most distinct miRNA in CD8+ cells is miR-30a-3p. Targets of the regulated miRNAs include genes in signalling pathways, e.g. phosphatidylinositol-3-OH kinase, the serine-threonine kinase Akt, mitogen-activated protein kinases and the Bcl-2 family of apoptosis regulators. Conclusions: The importance of regulation of the miR-17-92 cluster has been shown in immune cell development in humans. Furthermore, animal experiments have evidenced the involvement of the miR-cluster in murine autoimmunity. Our findings of altered expression of the miR-17-92 cluster in RRMS suggest a novel regulatory event in immunopathogenesis of MS, which is worth pursuing further and might provide more insights into the molecular mechanisms of MS pathology. Supported by: Swiss Multiple Sclerosis Society.
Hot Topic 3 Pediatric MS
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Clinical features of pediatric multiple sclerosis Sylvia Tenembaum
Pediatric Neurology, National Pediatric Hospital Dr. J. P. Garrahan, Buenos Aires, Argentina
The onset of multiple sclerosis (MS) in children and adolescents is being increasingly recognized worldwide. Nevertheless, the diagnosis of pediatric MS continues to be challenging given its protean clinical presentation and differential diagnosis. The central nervous system (CNS) inflammatory demyelinating disorders in pediatric patients include both self-limited and life-long conditions which can be misdiagnosed at the time of clinical onset. Current estimates suggest that children with MS account for up to 2.5 to 5% of all MS cases, according to several retrospective studies. The average age at clinical onset varies between 8 and 14 years. The female-to-male ratio is usually lower in children experiencing their first event under age 10 years than for the patients with juvenile-onset MS. Clinical presenting features of pediatric MS differ by age at onset as well. An acute demyelination with polyfocal features (ADEM-like phenotype) is usually described in younger children. Conversely, monofocal symptoms reminiscent of the typical features of adult-onset MS are more commonly observed in adolescents at first attack. Most patients experience a relapsing-remitting course, with relatively high relapse rate early in the disease. A prompt diagnosis of pediatric MS is important to optimize overall management of the physical and psychosocial impact of the disease. As there appears to be benefit in the early initiation of disease-modifying therapies in children, it is critical to accurately diagnose MS as early as possible, with an adequate exclusion of alternative diagnoses. This lecture will focus on the main clinical and MRI presenting features, clinical course and outcome of MS in pediatric patients, with particular attention to young children.
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Environmental influences and immunological features of multiple sclerosis in children Brenda Banwell
The Hospital for Sick Children, Toronto, Ontario, Canada
The pathobiology of multiple sclerosis (MS) is thought to involve a complex relationship between environmental triggers and host immune cell responses. Epidemiological studies have implicated place of residence during childhood as a key determinant of MS risk. As such, the onset of MS during childhood provides a unique opportunity to explore putative environmental contributions, and early host immune cell responses, in a population of MS individuals whose disease onset occurs in very close proximity to the inciting exposures. Data on viral seroprevalence, vitamin D, and on T cell responses to environmental and nutritional antigens in children with MS will be presented. 
Plenary Session 2 ECTRIMS Lecture
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What can we learn from treating multiple sclerosis? Chris Polman
Neurology, VU Medical Centre, Amsterdam, Netherlands I will present a combination of literature data and (partially unpublished) personal experiences on: The relevance of experimental allergic encephalomyelitis as an animal model for multiple sclerosis (MS), not only focussing on immune therapy-induced disease suppression but also including thoughts on disease exacerbation after suboptimal therapy and/or discontinuation of therapy. Early proof-of-concept studies of new interventions in MS. Can careful observations in only a small group of patients sometimes replace studies that are 'adequately powered'? The large phase III trials in MS: apart from the primary analysis of the primary outcome parameter, what can be learned from subgroup analyses and from additional, exploratory endpoints? Toxicity of treatments, expected and unexpected, and importance of adequate vigilance and management. Observations on treatments with approved drugs, on subgroups, on determinants of patient response, on long-term usage. Future analyses will determine how OCT imaging, using both current and new highresolution techniques, will provide insight into patterns and timing of axonal and neuronal loss in the visual pathways and will examine the potential effects of treatment.
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New insights into multiple sclerosis pathogenesis based on postmortem magnetic resonance imaging studies Frederik Barkhof
VUmc, Amsterdam, Netherlands
Magnetic resonance imaging (MRI) is widely used to diagnose multiple sclerosis (MS) and monitor disease activity and treatment. In order to enhance our understanding of the various MRI sequences and the interplay of tissue alterations in MS, post-mortem MRI offers a unique opportunity to study the pathology of MS in situ (cadavers) and ex vivo (brain slices). Its spatial resolution and tissue specificity provide a natural extension to the standard macroscopic evaluation (virtual autopsy) with the naked eye and may guide tissue sampling for microscopy. For example, the yield of actively demyelinating lesions can be increased using MRI-guided sampling. A significant proportion of abnormalities detected by post-mortem MRI are neither macroscopically visible nor palpable. The majority of these MRI-visible lesions represent either discrete areas of microglial activation with no demyelination (so-called (p)reactive lesions), or active demyelinating MS lesions at histopathology. The presence and extent of MS pathology in diffusely abnormal white matter (DAWM) outside focal demyelinated lesions is more readily appreciated by MRI-guided specimen sampling. DAWM on post-mortem images of the brain has been found to be associated with leakage of proteins through the bloodbrain barrier into the Virchow-Robin spaces in the presence of activated microglia, which may be an early event in lesion formation. Conversely, pathology correlation has been important to understand the limitations of MRI in the detection of cortical lesions (invisible even at 4.7 Tesla) and small spinal cord lesion (at 1.5 Tesla). In addition, post-mortem MRI can be used to validate new quantitative MRI techniques. The latter is of importance to establish the specificity of new MR techniques, such as diffusion tensor imaging (DTI), multicompartment T2 relaxation, and quantitative magnetic transfer imaging (qMTR). In conclusion, post-mortem MRI closes the gap between in vivo MRI observations and histopathology, bridging the knowledge derived from radiology and pathology. Background: Magnetic resoance imaging (MRI) markers that predict clinical disability are the subject of intense investigation. In clinically isolated syndrome (CIS) patients, T2 lesions predict clinical disability and cerebral atrophy 14 yrs later. 1 However in relapsing-remitting multiple sclerosis (RRMS) patients in the Phase 3 IFNB-1a trial, T2LL did not correlate with Expanded Disability Status Scale (EDSS) at 13 yr follow-up but did predict cerebral atrophy. 2 In this population, atrophy (brain parenchymal fraction [BPF]) was the best predictor of EDSS at 8 yr follow-up. In a study of 73 CIS, RRMS and secondary progressive multiple sclerosis (SPMS) patients, multivariate analysis demonstrated that change in magnetization transfer ratio (MTR) histogram metrics over 1 yr(rather than T2LL and BPF) predicted EDSS at 8 yr follow-up 3 . Objective: In this study, we have followed 31 MS patients with serial MRI examinations over 5 yrs to determine whether changes in whole brain MTR histogram metrics, BPF or T2LL predict clinical worsening. Methods: This retrospective study included 31 (28 RRMS; 3 SPMS) treatment-naive MS patients at baseline, followed by MRI and clinical exams. The patients (19 F: 12 M) were mean age 38.5 yrs, mean disease duration 2.8 yrs, and mean EDSS of 2.4 at entry. Ten patients remained untreated during the study, but the majority (70%) were treated with standard disease modifying therapies. Results: Seventeen patients remained clinically stable over 5 yrs (median EDSS ∆ 2.0 to 1.5). Fourteen patients showed a 2-point worsening from a median baseline EDSS of 1.5 to a median EDSS of 3.75 at 5 yrs (p=0.01). No significant differences in clinical or conventional MRI (cMRI)measures (contrast enhancing lesions or T2LL) distinguished these groups. However, BPF at baseline (p=0.05) and ∆ BPF over 5 yrs(p=0.003) correlated wtih clinical worsening. Similarly, ∆ whole brain MTR histogram mean over 5 yrs correlated with clinical worsening(p=0.006). Conclusions: In RRMS patients, particularly those treated with therapies that suppress lesion formation, MRI measures of tissue damage e.g. atrophy and MTR show a more robust correlation with clinical disability than cMRI. 1 (T1w) images, quantitative T2 maps and GEPCI-FLAIR images that are naturally co-registered. Objective: To determine whether the GEPCI technique yields substantial improvement in quality and time required for evaluation of multiple sclerosis (MS) as compared with standard protocols. Methods: Brain images were acquired on MS subjects using a Siemens 1.5T Magnetom Sonata system. Standard clinical T1w, T2w and FLAIR images were obtained with a voxel size of 1.3×0.9×3mm3. 3D multi-gradient-echo GEPCI sequence with a similar resolution (1×1×3mm3) was then performed. A total of 13 gradient-echo images with echo spacing of 3.4ms were acquired with TR = 50ms and flip angle = 30°. T1w images and quantitative T2 maps were then generated. A threshold to remove the cerebrospinal fluid signal was applied to produce quantitative GEPCI-FLAIR images. Results: Similar lesion distributions were observed when comparing standard T2w and FLAIR images with T2 maps and GEPCI-FLAIR images. On the T1w images, all hypointense lesions detected by T1w SE were observed by T1w GEPCI, but GEPCI also revealed additional hypointense lesions confirmed as MS lesions by T2w and FLAIR imaging. Gray-white matter contrast was also improved with T1wGEPCI, allowing better identification of the relative position of MS lesions. The acquisition time for simultaneous generation of T1w, T2 maps and GEPCI-FLAIR images was considerably reduced compared with equivalent SE sequences (8min32s for GEPCI against 15min49s for standard protocol). Conclusions: We propose a new MRI method (GEPCI) for evaluation of MS disease burden which provides improved images with enhanced detection of MS lesions in less time compared with current clinical protocols. Moreover, GEPCI offers the possibility to investigate on a quantitative basis the complex correlation between tissue MR relaxation times and pathologic substrates underlying MS lesions. Supported by: National Multiple Sclerosis Society (USA) (CA 1012). NIH grant UL1 RR024992. We aim to disclose the spatiotemporal relationship between macrophage infiltration and breakdown of the blood-brain barrier (BBB) as indicated by Gf enhancement in EAE. Methods: EAE was induced by immunization with myelin oligodendrocyte protein in 17 Dark Agouti rats. When the first clinical symptoms appeared SPIO was administered intravenously. Cranial and spinal MRI was performed using T1-w and T2-w high resolution sequences on a 1.5T MR scanner 24 h later. To allow for direct comparison Gf was injected into the same animals thereafter and MRI was repeated 24 h later. Results: On T1-w MRI, Gf-enhancement indicating leakage of the BBB was consistently found in numerous areas of the spinal cord, brain stem, cortex and optic nerves. Gf-uptake closely corresponded to lesions with macrophage infiltration and albumin extravasation on tissue sections. Notably, SPIO accumulation was only observed in a small portion of the Gf enhancing lesions in 4 of 17 animals. Vice versa, many areas showing signal loss on T2*-w MRI indicative of macrophage entry did not exhibit Gf enhancement. Conclusions: In conclusion, we can reinforce previous observations that macrophage infiltration and BBB leakage occur independently in EAE. Macrophages can obviously infiltrate the central nervous system in areas with an intact BBB. This may have implications for future MRI monitoring of disease activity in MS. Supported by: This work was supported by the Gemeinnützige Hertie-Stiftung, Frankfurt/Main and a professorship for neuroimaging to M.B. donated by Bayer-Schering Pharma AG to the University of Wuerzburg.
Parallel Session 6 Predicting outcomes in MS
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Clinical and demographic predictors of early multiple sclerosis course Emmanuelle Waubant
UCSF, San Francisco, California, USA
Within an individual multiple sclerosis (MS) patient, active lesions tend to be of the same pathologic category. Whether such individual homogeneity exists at the clinical level is not known. Although poor first demyelinating event recovery and early relapse predict a worse long-term outcome, the determinants of relapse recovery and frequency are not well understood. We approached these questions by scoring the anatomical location, severity and recovery of first, second and third demyelinating events in patients seen within the first year of MS onset. First, non-white race/ethnicity and younger age were significantly associated with severe first and second events. Predictors of a complete recovery of the first and second demyelinating event were event severity. Second, and most importantly, a severe initial event predicted more severe second and third events (respectively, OR=5.66, 95%CI [2.38, 13.49], p<0.0001; OR=7.65, 95%CI [1.87, 31 .27], p=0.0046). Similarly, poor initial event recovery predicted poorer recovery of the second and third events (respectively, OR=7.58, 95%CI [2.74, 20 .98], p<0.0001; OR=11.07, 95%CI [1.64, 74 .51], p=0.0135). Third, there was an increased odds of a patient's second and third relapses occurring in the same anatomical location as the first event. Finally non-white race/ethnicity and younger patients also had a higher risk of relapse during the first year of onset (respectively HR=2.39, 95%CI [1.58, 3 .60], p<0.0001; HR for each 10-year decrease in age = 1.51, 95%CI [1.28, 1.80], p<0.0001). These data suggest that younger patients and nonwhites tend to have more severe presentation in terms of event severity and frequency. In addition, there is an inherent tendency for patients with severe presentation and poor recovery, or specific central nervous system attack locations at disease onset, to have the same relapse characteristics during subsequent demyelinating events. Whether genetic or biological factors are responsible for this pattern remains to be determined.
Background:
The Multiple Sclerosis Severity Score (MSSS) is the Expanded Disability Status Scale (EDSS)-based severity rank for a given disease duration. Roxburgh et al 1 suggested that the MSSS can be used to compare MS severity in large groups of patients for the purposes of, for example, genetic studies of putative disease modifier genes. However, a high rank stability would also suggest utility as an individual outcome predictor. Objective: To assess the stability of MSS scores in the MSBase dataset, a large multi-center cohort study of MS outcomes. Methods: Data was extracted on 4th of April 2008. The dataset comprised 6100 patients with all forms of MS, with 38,683 complete EDSS scores. In individuals, multiple EDSS scores recorded within a specified disease duration interval were averaged. We used the 0-2.5 year interval as 'diagnosis', the 2.5-7.5 year interval as '5-year duration', the 7.5-12.5 year interval as '10-year duration' and the 12.5-15 year interval as '15-year duration'. Groups of patients with EDSS scores spanning these pre-specified disease duration intervals were analysed. Patients were ranked within each interval and 5-year MSSS stability assessed using Spearman rank-sum correlations. Rank stability was also assessed descriptively as the proportion of patients remaining within 15% of their original rank in sequential 5-year intervals. Results: Mean EDSS scores were 2.02 at diagnosis, 2.67 at 5 years, 3.15 at 10 years and 3.49 at 15 years. Spearman rank-sum correlation between MSSS at diagnosis and 5 years was r=0.66 (1692 patients), between 5 and 10 years r=0.80 (1546 patients) and between 10 and 15 years r=0.88 (893 patients). In the diagnosis-5 year interval, 60% of patients remained within 15% of their original MSSS. In the 5-10 year interval, this increased to 75% and, in the 10-15 year interval, to 83%. Conclusions: MSSS rank stability increases with increasing disease duration, probably due to reduced influence of relapses and nonrelapse fluctuations of mild neurological signs on EDSS evaluations. MSSS at 5 years from diagnosis is already highly predictive of MSSS at 10 years, and may therefore have predictive prognostic value in individual patients. While we are still in urgent need of efficient interventions targeted at protecting against demyelination and axonal loss and of course treatments promoting remyelination/regeneration, significant advance is observed regarding both selectivity and efficiency of interventions targeting systemic immune dysfunction, disturbance of the bloodbrain-barrier and more or less directly the inflammatory process in the CNS. Natalizumab was the first monoclonal antibody to enter everyday practice in MS. Designed to block the entrance of immune cells into the CNS it has had an impressive effect on both inflammatory disease activity in MRI and relapse rates but also in slowing down progression of impairment and disability over 2 years of treatment. Ongoing safety evaluations after the occurrence of JC virus infections will help to better position this new drug in relation to available treatments. Other monoclonal antibodies and recombinant ligands targeting B cells (Rituximab, Ocrelizumab, Ofatumumab, Atacicept), molecules at the immunological synapse (Daclizumab) or a broad variety of immune cells (Alemtuzumab) have shown promising results in proof of concept phase II studies and are currently entering or already well in Phase III. By no means less remarkable are phase II results of a number of oral immunomodulators: FTY720, Teriflunomide, Laquinimode, Temsirolimus, Fumarate or the cytostatic agent Cladribine. These emerging new oral agents promise to both increase efficacy, and decrease the burden of inconvenience and side effects, thus allowing earlier treatment and better long term compliance. Developing an evidence based approach to their differential indication and combination of this increasing number of therapeutic options, will be the challenge in the forthcoming years.
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Treatments that target macrophages and microglia
Samia Khoury
Brigham and Women's Hospital, Boston, Massachusetts, USA Macrophages and activated microglia cells are the key effectors for tissue injury in inflammatory conditions of the central nervous system (CNS). Microglia share many phenotypical and functional characteristics with other tissue macrophages and with peripheral blood monocytes. Reactive microglia play a significant role in the initiation and propagation of immune responses as the inflammatory mediators during the process of inflammation in the CNS. Microglial response to extracellular stimuli is mediated by kinase and phosphatase cascades. Activated microglia are present in multiple sclerosis (MS) lesions and its animal model experimental autoimmune encephalomyelitis (EAE), where chronically activated microglia appear to impact the repair potential of neural stem cells. Treatments that target microglia activation have a positive impact on EAE. Compounds that inhibit microglia activation include glucocorticoids, minocycline, vitamins A, D, and E, chondroitin sulfate, endocannabinoids, PPAR-gamma agonists, and anti-CD200 antibodies. Several of the drugs and molecules described suppress the neurotoxic effect of microglial cells in EAE. For these targets to become viable therapeutic options for MS and other CNS diseases would require that they cross the blood-brain barrier and target functional properties of the CNS antigen-presenting cells and at the same time have limited toxicity.
Alemtuzumab significantly increases the proportion of clinically disease-free patients with relapsing-remitting multiple sclerosis compared with subcutaneous interferon beta-1a: results from a phase 2 study Krzysztof Selmaj, on behalf of the CAMMS 223 Study Group.
Klinika j Katedra Neurologii Akademii, Lodz, Poland
Background: CAMMS223, a randomized, open-label, rater-blinded trial compares the safety and efficacy of annual alemtuzumab (alem) with that of 3 times/week SC interferon beta-1a (IFNB-1a) in treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS). Objective: Prior 3-year analyses of relapse and 6-month sustained accumulation of disability (6-month SAD: increase in Expanded Disability Status Scale (EDSS) score of ≥1.5 if baseline EDSS=0, ≥1.0 if baseline EDSS ≥1.0, lasting ≥6 months) showed alem was significantly more effective than IFNB 1a. Analyses of 'clinically disease-free' and additional relapse and disability outcomes from the study's first three years are presented. Methods: 334 patients were randomized 1:1:1 to: 3 times/week SC IFNB-1a 44 mcg; 24 mg/day alem; 12 mg/day alem. Alem was intravenously administered once/day for 5 days at Month 0, 3 days at Month 12, and in some patients, 3 days at Month 24. Entry criteria included disease onset within 3 years, EDSS ≤3.0, ≥2 MS episodes within 2 years, and ≥1 enhancing lesion on screening magnetic resonance imaging. EDSS and relapse evaluations were performed blind by neurologists. Data from the alem arms were pooled. 'Clinically disease-free' was defined as the absence both of relapses and disability progression (ie, EDSS increase lasting ≥3 months) during the time period assessed. Results: Alem significantly increased the proportion of relapse-free, 3 month SAD-free, and 6 month SAD-free patients at years 1 through 3 compared with IFNB-1a (p-values <0.0001). Moreover, the proportion of clinically disease-free patients was significantly higher in the alem group than the IFNB-1a group at years 1 (86% alem vs 63% IFNB 1a), 2 (81% alem vs 48% IFNB-1a), and 3 (71% alem vs 38% IFNB-1a, p values <0.0001). Alem-related adverse events included infusion reactions, immune thrombocytopenic purpura, thyroid dysfunction, and predominantly mild and moderate infections. Conclusions: Alem was significantly better than IFNB-1a at achieving a clinically diseasefree state for patients with RRMS. Effects were evident early in the first year and sustained through year 3. Background: Autologous T-cell vaccination uses attenuated myelin reactive T cells (MRTC) to induce anti-idiotypic and anti-ergotypic immune regulatory responses which clonally deplete and regulate circulating myelin-reactive T cells (MRTC) . An open-label phase 1-2 dose-escalation trial of Tovaxin has shown statistically significant improvements from baseline for ARR and peptide-specific MRTC reduction with only rapidly resolved mild injection site adverse reactions. Objective: To evaluate the efficacy, safety, and tolerability of Tovaxin® T-cell vaccination in clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS) patients. Methods: This phase 2b trial randomized and treated 150 patients with CIS (10 patients) or RRMS (140 patients) in 33 centers in the United States as a double-blind, placebo-controlled, 2-arm, 52-week, and parallelgroup study of Tovaxin compared with placebo. Patients in the trial were treated with subcutaneous injections at 0, 4, 8, 12, and 24 weeks. The study was designed to assess primary and secondary endpoints on weeks 28, 36, 44 and 52. Analyses are to be performed at the end of the 52-week study in August, 2008, to assess the safety and efficacy of Tovaxin treatment. Results: Top-line results for the 12-month study will be presented for the primary efficacy variable of cumulative number of T1 gadolinium-enhancing magnetic resonance imaging (MRI) lesions summed over the Week 28, 36, 44, and 52 MRIs and the secondary efficacy variables of cumulative number of new gadolinium-enhancing lesions at Weeks 28-52 and change in T2-weighted lesion volume. Additional MRI variables of T1-weighted lesion volumes, T1-gadolinium-enhancing lesion volumes, proportion of T1-gadolinium-enhancing lesions present at baseline evolving into T1-hypointense lesions (black holes) at week 52, and percent brain volume change will also be presented. Conclusions: The TERMS study is the first to compare the efficacy of T-cell vaccination in a placebo-controlled multicenter trial. The results of the study will guide the development of further clinical trials of Tovaxin. Supported by: Opexa Therapeutics. Background: Neurodegenerative diseases of the central nervous system and the degenerative phase of multiple scerosis (MS) are less amenable to treatment modalities. Neuroprotective approaches for such diseases could provide a solution and are currently under investigation. Bone marrow (BM) derived mesenchymal stem cells (MSC) possess strong neurotrophic and immunomodulatory properties. They were beneficial in several experimental models of neurological diseases, and specifically were very efficient in suppression of experimental allergic encephalomyelitis, the animal model of MS. The ability to easily obtain MSC from the patient, expand them in culture and re-introduce them as an autologous graft, as well as the lack of risk for malignant transformation make these cells excellent candidates for cell therapy. Objective: To evaluate the feasibility and safety of intrathecal administration of BM-MSC in patients with severe MS and with amyotrophic lateral sclerosis (ALS). Methods: Thirteen MS patients with a mean EDSS score of 6.8 and 14 ALS patients with a mean ALSFRS score of 22.0 were included in this trial. Following culture of the cells for 40-90 days in a Clean Room facility (GMP), BM-MSCs were cryopreserved until sterility was confirmed after additional 14 days. All patients received intrathecally a mean of 64.4 million cells. Ten patients were injected also intravenously with MSC. Results: In 20 patients there were injection-related side effects of transient meningeal irritation and mild fever which lasted for 1-2 days. No major side effects were reported during a follow up period of up to 25 months. The mean ALSFRS remained stable during the 6 first months of observation (22.1-22.6), whereas the mean EDSS score improved to 6.0 and 5.7 at 3 and 6 months respectively. Conclusions: This is the first trial with intrathecal injection of MSC in MS and ALS and shows the safety and feasibility of the procedure. Further controlled studies and longer observation periods are needed to evaluate possible efficacy and long term effects of this treatment.
The first disease-modifying therapy for multiple sclerosis (MS) was licensed in 1993. Approved therapies now include the immunomodulator beta interferons and glatiramer acetate, the immunosuppressant mitoxantrone, and the monoclonal antibody natalizumab. Used early in relapsing disease these drugs reduce the frequency of clinical relapses, magnetic resonance imaging-detected lesion activity, and may slow accumulated disability. All resulted from the application of randomized, blinded, multi-centered, placebo-controlled trial designs that were not adequately adapted for the study of MS until the 1980s. Available agents are only partially effective, expensive, injectable, and associated with troublesome side-effects; potentially better therapies are under development. Ironically, partially effective therapies impede continued rapid advances. A diminishing eligible patient pool has driven registration trials to enroll sites and subjects in geographic areas where phase III trials are rather novel and available drugs poorly accessible. The placebo-controlled trial remains an incisive, costeffective, ethically defensible, and scientifically justifiable approach to determine the risk/benefit of innovative therapy. Alternative trial designs for MS remain largely untested. Superiority trials are viable alternatives. Non-inferiority studies demand unacceptably large numbers of subjects to achieve at best marginal benefit. Combination of an innovative therapy plus an approved agent can prove superiority to monotherapy, but fail to define if combined therapy is essential without a placebo-only cohort. In the absence of validated surrogate markers, current trials must rely on clinical outcomes: relapses and/or persistent accumulated neurologic deficit; the latter being difficult to measure in trials with durations of less than three years. The promise that expression profiling may enrich studies with responds remains unproven. Until new tools evolve from current studies, novel trial designs of adaptive duration with entry criteria based on potentially informative subject demographics exclusive of current clinical phenotypes and conditional interim analyses might provide the best step forward.
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The ethics of clinical trials in developing countries Edgardo Cristiano
Neurology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
The ethical principles and guidelines to protect human subjects of research are governed by the declaration of Helsinki and the Belmont report. These principles are now universally accepted and assumed as the guiding principles of respect for persons (recognition of the right of individuals to exercise their autonomy), beneficence (minimization of risk to which they described as research subjects and maximizing the benefits for them and others) and justice (the principle that therapeutic research should not involve persons and/or countries that probably will not benefit from applications resulting from research). Currently, developing countries offer conditions that are conducive to research by the pharmaceutical industry: lower costs, less time and greater availability of research subjects. Less demanding legislations, lack of thoroughness of some ethics committees, some irresponsible researchers and prejudices of the population regarding clinical research are factors that make it more difficult to seek compliance with these principles in Latin America. Reconciling these tensions is an urgent and unavoidable challenge that will allow us to develop unique and universal ethics, rather than proposing different ethical principles for different countries and scenarios. The objective of the definition of treatment response is to select earlier non-responders. Patient response outcomes should be measured taking into consideration interfering factors related to the disease itself. Several criteria for treatment response to interferon beta (IFNb) have been proposed. Nevertheless, these different criteria have not been validated and there is no consensus among different investigators. Long-term disability data are crucial in order to select the most clinically meaningful definition. These criteria are based on relapses, disability progression or both. Several factors make the employment of relapse outcomes to determine therapeutic response difficult (low predictive value, regression to the mean, etc.). The progression of neurological impairment is another criterion employed to quantify response; however efficacy fluctuations related to depression, fatigue, spasticity, concurrent illness and prolonged relapse need be excluded. Nevertheless, criteria of response to IFNb therapy using disability progression are more clinically relevant than those based only on relapse rate. On the other hand, there are limited prospective data to validate magnetic resonance imaging (MRI) measures of disease activity as reliable prognostic factors of suboptimal response to therapy, but MRI changes which occur during the first months of IFN therapy may have a prognostic value for identifying patients with a confirmed increase of disability in the next years of therapy. Several factors are related to response from multiple sclerosis (MS) heterogeneity to genetic load and IFN response genes to poor healing mechanisms. In conclusion, in relation to response to therapy in MS patients, the proportion of non-responders varies depending on the definition used and criteria based on relapse measures have poor sensitivity and positive diagnostic value. Non-responders have a higher clinical activity at baseline, and baseline Expanded Disability Status Scale (EDSS) predicts long-term disability. There are limited prospective MRI data as predictors of therapeutic response, and the early confirmation of EDSS increase may be a clinical marker of poor response.
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Management of treatment failure Richard A. Rudick
Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA Early diagnosis and treatment is common for multiple sclerosis (MS) patients. The rationale includes recognition that focal inflammation is accompanied by irreversible axonal injury, which contributes to progressive brain and spinal cord atrophy. Effective early control of MS-related central nervous system inflammation may yield important long-term therapeutic benefits. One definition of treatment failure is any degree of clinical or magnetic resonance imaging (MRI) disease activity despite the use of disease-modifying drug therapy (DMDT). Complete remission is the optimal result from treatment. While MRI monitoring is common practice and necessary to demonstrate disease inactivity, there is no class I evidence demonstrating the benefits of MRI monitoring in managing DMDT in MS. Also, defining complete disease remission is not always easy; relapses are not always clear-cut events, there are no quantitative measures of T2 lesion number and volume readily available in the clinic, gadolinium-enhancing lesions may be sporadic, gray matter pathology is not visualized with standard MRI, etc. Despite these problems, common definitions of treatment failure have emerged. These include relapses despite DMDT, MRI activity despite DMDT, or both. A practical definition of treatment failure, applicable for patients in a clinical setting, will be provided. Possible approaches to DMDT in patients with treatment failure will be reviewed: 1) Switching between ABCR drugs; 2) Adding drugs to an ABCR drug to create combination drug therapy; or 3) Advancing treatment from ABCR monotherapy to natalizumab or mitoxantrone (or other potent immunosuppressive drugs). Patients with disease activity while on interferon (IFN) therapy should be tested for the presence of IFN-neutralizing antibodies. Recent studies have highlighted toxicities associated with combination therapy (e.g. the SENTINEL Study; a trial of cladribine in combination with Rebif). The Avonex Combination Trial failed to demonstrate significant benefits of combining Avonex with methotrexate, methylprednisolone, or the combination in patients with relapses despite Avonex monotherapy. Ongoing trials of combination therapy for patients with disease activity despite standard therapy will be reviewed.
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A post-marketing evaluation of the impact of neutralizing antibodies on the effectiveness of interferon beta in relapsingremitting multiple sclerosis Damiano Paolicelli cardio-vascular function and endurance. In spite of the large body of research demonstrating that exercise is safe and does not cause exacerbations, patients and physicians are still often fearful of this modality. However, it is the lack of appropriate exercise that is detrimental in MS, rather than too much exercise. In general, it is advisable for persons with MS to exercise over short periods of time, and to focus on a small number of muscles during any given session. Persons with MS should also keep as cool as possible during exercise. Reducing post-exercise fatigue through shorter sessions and body cooling represent the major differences between exercise recommendations for persons with MS and the general population.
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Rehabilitation of cognitive impairment Alan J. Thompson
Institute of Neurology, UCL, London, United Kingdom
Cognitive impairment is a frequent occurrence in all forms of multiple sclerosis (MS) though may be quite subtle early in the course of the condition. Typically, attention, information processing (particularly speed), new learning and memory are most affected. The impact of cognitive impairment is considerable both directly in term of function and daily activities but also in the ability of the individual to mange the manifestations of MS. It can have a profound impact on occupation, quality of life and coping skills and can interact in a complex fashion with other common symptoms such as fatigue and depression. Of the many challenges inherent in the management of cognitive impairment, the ability to characterise the extent of the abnormalities and to measure them both in clinical practice and within clinical trials is the most fundamental to the evaluation of management strategies There has been a number of different approaches to the management of cognitive impairment, though not many have been rigorously assessed. Interpretation of studies is limited by the large number of outcome measures used, Recent reviews (I,2) of the limited number of rigorous studies (class I and II) of patients with cognitive impairment have suggested some benefit in the area of verbal learning and memory. Benefits from both psychotherapy and cognitive behavioural therapy were seen in depression, while some benefit from the latter was also seen in improving coping skills Cognitive rehabilitation is still in its infancy and more methodologically rigorous research is needed to determine the efficacy of specific therapeutic interventions 1. The contribution of MS literature in cognitive issues in LA is scarce. Only 2% of the 547 medline indexed papers related to CD were from LA. Most of these papers are methodologically heterogeneous using different neuropsychological tests. However, the CD frequency is very similar among them affecting 45-60% of the MS population. The most affected cognitive domains are memory, attention, visual perception, information processing speed, and executive function. Conclusion: Even with an increasing interest in MS in LA, more multicenter studies are needed. and by calculating a cognitive impairment index (CII). The following MR parameters were analyzed: CL number and volume (CLv), T2 white matter lesion volume (T2-WMLV), gadolinium enhancing lesions, gray matter fraction and white matter fraction. Depression (Beck Depression Inventory Scale (BDI)) and fatigue (Fatigue Impact Scale (FIS) and Fatigue Severity Scale (FSS)) were also investigated. Results: Twenty-four patients had a score below two standard deviations of control mean value in at least one cognitive test. CLs were observed in 63 patients. A moderate correlation was found between CLv and CII (r=0.649, p<0.001), in particular with SRT-CLTR (r=-0.446, p<0.001), SDMT (r=-0.541, p<0.001), Pasat-3" (r=-0.532, p<0.001), WLG (r=-0.385, p=0.001). A multivariate analysis revealed that CLv, age and T2-WMLV were independent predictors of cognitive impairment. In cognitively impaired patients, CLv was significantly higher (730±360 mm 3 ) than in cognitively normal patients (408±325 mm 3 , p<0.001). No correlation was observed between CLv and fatigue, which was found to correlate weakly with T2-WMLV (r=0.341, p=0.007 for FSS and r=0.367, p=0.004 for FIS). Depression did not correlate with any of the tested MR parameters. Conclusions: Our findings indicate that intracortical lesion load is likely to be one of the major determinants of cognitive impairment in MS.
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Longitudinal imaging of gray matter lesions in multiple sclerosis and the relation with neurocognition Stefan D. Roosendaal, Bastiaan Moraal, Hugo Vrenken, Petra J. Pouwels, Jonas A. Castelijns, Frederik Barkhof, Jeroen J. Geurts
VU University Medical Center, Amsterdam, Netherlands
Background: New MRI sequences, such as double-inversion recovery (DIR), have been shown to substantially improve the detection of gray matter (GM) lesions in multiple sclerosis (MS). GM lesions were found to be abundant and occur early in the disease course. However, so far little is known about the progression of GM lesions over time. Objective: To study the development of GM lesions within three-year follow-up, using 3D-DIR images and to explore whether the number of GM lesions is associated with cognitive decline. Methods: 3DDIR
